PharmiWeb5h
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
JD Supra16h
FDA Accepts U.S. Biologics License Application for AVT06, Alvotech and Teva’s Proposed Aflibercept Biosimilar
Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...
BioPharma Dive18h
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
ICLR DEADLINE: ICON plc Investors are Alerted to Contact BFA Law before Imminent April 11 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain ...
TMDX DEADLINE: TransMedics Group, Inc. Investors are Alerted to Contact BFA Law before Imminent April 15 Class Action Deadline
New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...
manilatimes3d
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
SELARSDI is approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...
Le Lézard3d
Teva and Alvotech Announce SELARSDItm (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDItm for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination ...
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW ...
Teva Pharmaceutical Industries Ltd: Putting Patients First: Why Europe Must Act to Protect Access To Medicines
New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are supplied by only one provider. This ...
PharmiWeb5d
PUTTING PATIENTS FIRST: WHY EUROPE MUST ACT TO PROTECT ACCESS TO MEDICINES
WHY EUROPE MUST ACT TO PROTECT ACCESS TO MEDICINESAmsterdam, 20 February 2025 New research by Teva Pharmaceuticals Europe shows that 46% of generic medicines from the EU Critical List of Medicines are ...
Is Teva Pharmaceutical (TEVA) Trading at a Discount?
Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
DelveInsight Business Research, LLP: Global Transmucosal Drugs Market to Reach ~USD 28 Billion by 2032 | DelveInsight
The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...